These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 27450893)

  • 1. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
    Dhawan M; Ryan CJ
    Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
    Bambury RM; Rathkopf DE
    Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer.
    Antonarakis ES
    Clin Adv Hematol Oncol; 2016 May; 14(5):316-9. PubMed ID: 27379691
    [No Abstract]   [Full Text] [Related]  

  • 4. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 6. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).
    Penning TM
    J Steroid Biochem Mol Biol; 2015 Sep; 153():105-13. PubMed ID: 26032458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
    Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV
    Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
    Kosaka T; Oya M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer].
    Szarvas T; Csizmarik A; Nagy N; Keresztes D; Váradi M; Küronya Z; Riesz P; Nyirády P
    Orv Hetil; 2020 May; 161(20):813-820. PubMed ID: 32364360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?
    Tsaur I; Borgmann H; Surcel CI; Ost P; Ploussard G
    World J Urol; 2018 Jan; 36(1):149-151. PubMed ID: 29086020
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen receptor aberrations in the era of abiraterone and enzalutamide.
    Jentzmik F; Azoitei A; Zengerling F; Damjanoski I; Cronauer MV
    World J Urol; 2016 Mar; 34(3):297-303. PubMed ID: 26100946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
    De Laere B; Rajan P; Grönberg H; Dirix L; Lindberg J;
    JAMA Oncol; 2019 Jul; 5(7):1060-1062. PubMed ID: 31046065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
    Tombal B
    Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
    [No Abstract]   [Full Text] [Related]  

  • 16. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
    Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
    Antonarakis ES
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):143-5. PubMed ID: 25547524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.
    Rezaei S; Mahjoubin Tehran M; Sahebkar A; Jalili A; Aghaee-Bakhtiari SH
    J Cell Physiol; 2020 Apr; 235(4):3222-3234. PubMed ID: 31599460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
    Boegemann M
    Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.
    Luo J; Attard G; Balk SP; Bevan C; Burnstein K; Cato L; Cherkasov A; De Bono JS; Dong Y; Gao AC; Gleave M; Heemers H; Kanayama M; Kittler R; Lang JM; Lee RJ; Logothetis CJ; Matusik R; Plymate S; Sawyers CL; Selth LA; Soule H; Tilley W; Weigel NL; Zoubeidi A; Dehm SM; Raj GV
    Eur Urol; 2018 May; 73(5):715-723. PubMed ID: 29258679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.